All lobbying filings

DLA PIPER LLP (US)

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Trade association of innovative biopharmaceutical research companies.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $60,000.00 income · posted Jul 20, 2026

Official filing document

Bills named in this filing 1

S 832
EPIC Act of 2025

Lobbying activity 7

Intellectual property protections and enforcement. Biopharmaceutical patent policy.

Budget/Appropriations

Healthcare provisions in appropriations and budget legislation.

Defense

National security issues related to pharmaceutical industry, including supply chain.

Trade (domestic/foreign)

Trade policies and agreements, including IP protections, and administrative tariff actions.

Pharmacy

Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.

Health Issues

S. 832, EPIC Act of 2025. Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.

Medicare/Medicaid

Medicare policies.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.